hotspot -WSS

hotspot

author：leisure time 2025-10-02 18:49:25 - browse：8846

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

hotspot

WSS

Steward Health Care has deal to sell doctor network to UnitedHealth

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Pharma companies must ensure equitable access to obesity drugs

Statins may not be needed by millions of people, study suggests

Readers discuss the intersection of pregnancy and addiction

Scientists boost immune system in aging mice by making it youthful

leisure time

hotspot

leisure time

Medical records are filled with copy

NIH tests clinical research in primary care with $30 million program

After affirmative action ruling, medical educators look to 'holistic review'

STAT Virtual Event: ASCO Recap, Live!

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eliminate the waiting period for sterilization covered by Medicaid

Novavax promises a turnaround & Lilly roils the obesity market

Readers discuss the intersection of pregnancy and addiction

Medicare details structure of new drug price negotiation program

Statins may not be needed by millions of people, study suggests

focus

NIH tests clinical research in primary care with $30 million program

Abortion pill case raises question: who can sue the FDA?

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Moderna says combo Covid

NIH tests clinical research in primary care with $30 million program

focus

Wikipedia

hotspot

focus